Bernard Hojaili
Rheumatology · New Iberia, LANPI 1659456242
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,195 of the $13,042 with a category attached, or 70.5%. 26 manufacturers reported payments, led by AbbVie at 26.9% of the total.
Across 498 payments — averaging $26.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Johnson & Johnson$3K
- Amgen$3K
- Mallinckrodt Hospital Products Inc.$696
- Novartis$624
- Aurinia Pharma U.S., Inc.$476
- plus $2K from 20 others
What the payments were for
- Consulting fees$2,52519%
- Speaking & faculty fees$7005%
- Travel & lodging$3082%
- Food & beverage$9,19571%
- Education$3142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 147 | $3,502 |
| Johnson & Johnson | 21 | $2,757 |
| Amgen | 143 | $2,622 |
| Mallinckrodt Hospital Products Inc. | 23 | $696 |
| Novartis | 29 | $624 |
| Aurinia Pharma U.S., Inc. | 23 | $476 |
| ANI Pharmaceuticals, Inc. | 22 | $395 |
| UCB, Inc. | 17 | $369 |
| Pfizer | 15 | $367 |
| GSK | 17 | $311 |
| Fresenius Kabi USA, LLC | 11 | $217 |
| Lilly USA, LLC | 6 | $143 |
| Boehringer Ingelheim | 6 | $126 |
| Cardinal Health 110 LLC | 1 | $100 |
| Janssen Scientific Affairs, LLC | 2 | $87 |
| AstraZeneca | 3 | $53 |
| Exact Sciences | 2 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $28 |
| Radius Health, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Corium, LLC | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$2,308
- SIMPONI ARIA$2,308
- Skyrizi$775
- Rinvoq$350
How this compares
$13,042 in reported general payments places this provider in the 60th percentile of 88 rheumatology providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 426 | $4,527,716 |
| RinvoqUpadacitinib | 213 | $1,342,287 |
| Enbrel SureclickEtanercept | 147 | $1,076,194 |
| BenlystaBelimumab | 197 | $943,136 |
| Humira(Cf)Adalimumab | 25 | $213,064 |
| Actemra ActpenTocilizumab | 44 | $196,179 |
| OtezlaApremilast | 41 | $187,653 |
| LupkynisVoclosporin | 12 | $175,118 |
| Orencia ClickjectAbatacept | 15 | $94,727 |
| Cimzia (2 Pack)Certolizumab Pegol | 16 | $88,531 |
| Xeljanz XrTofacitinib Citrate | 13 | $72,603 |
| Mycophenolate Mofetil | 474 | $56,394 |
| Hydroxychloroquine Sulfate | 1,580 | $46,061 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,012 | $26,113 |
| RasuvoMethotrexate/Pf | 39 | $22,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Restasis Multidose, Restasis, Savella | $3,502 | $1,576,298277 claims |
| GSKBenlysta | $311 | $943,136197 claims |
| AmgenOtezla | $2,622 | $187,65341 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $476 | $175,11812 claims |
| UCB, Inc.Cimzia (2 Pack) | $369 | $88,53116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in New Iberia
- Aaron BroadwellShreveport$1.6M
- Ladislas LazaroLafayette$265K
- Jerry PoundsMetairie$252K
- Carl GauthierHammond$219K
- Malik SpadyCovington$160K
- Sean ShannonBaton Rouge$157K
- Stephen LindseyBaton Rouge$130K
- Agnes SolonAlexandria$123K
- Randall BeylBaton Rouge$112K
- Frankie PedigoShreveport$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.